Brief: Galectin Therapeutics Final Randomization Status Of Navigate, Its Seamless, Adaptive Phase 2B/3 Study Of Belapectin In Cirrhosis Patients
02/03/2023 13:08
March 2 (Reuters) - Galectin Therapeutics Inc GALT.O :
* FINAL RANDOMIZATION STATUS OF NAVIGATE, ITS SEAMLESS,
ADAPTIVE
PHASE 2B/3 STUDY OF BELAPECTIN IN PATIENTS WITH LIVER CIRRHOSIS
* TOPLINE RESULTS OF INTERIM ANALYSIS ARE EXPECTED IN Q4 OF
2024
* TOPLINE RESULTS OF INTERIM ANALYSIS ARE EXPECTED IN Q4 OF
2024
Further company coverage: GALT.O
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study